Sorafenib tosylate in advanced kidney cancer: Past, present and future

Camillo Porta, Chiara Paglino, Ilaria Imarisio, Elisa Ferraris

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The objective of this paper was to review the development of sorafenib tosylate in kidney cancer. The MedLine database, the Proceedings of the Annual American Society of Clinical Oncology meeting, as well as those of other key international meetings were extensively searched to identify relevant publications. Furthermore, the authors' direct experience with the drug was taken into account when commenting on the results retrieved. Sorafenib is a multikinase inhibitor that targets VEGF and PDGF receptors, other kinases, as well as the serine-threonine kinase Raf. Following early signs of activity from phase I and II studies, it has been shown to improve survival of pretreated advanced kidney cancer patients within a placebo-controlled, randomized, phase III trial, leading to its approval both in the United States and in Europe. Its activity has been subsequently confirmed in a real-world population by two expanded access programs performed globally, but not in a first-line setting; it also proved to be non-cross-resistant with two other molecularly targeted agents. Finally, its toxicity profile, which is acceptable and highly predictable, makes sorafenib appealing for combination treatments, especially with other molecularly targeted agents. Despite having been already demonstrated to be active in kidney cancer, the exact role of sorafenib in the first-line setting, in patients who have failed other molecularly targeted agents, and especially in combination with other agents, deserves further, prospective, studies.

Original languageEnglish
Pages (from-to)409-415
Number of pages7
JournalAnti-Cancer Drugs
Volume20
Issue number6
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Kidney Neoplasms
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Protein-Serine-Threonine Kinases
Publications
Phosphotransferases
Placebos
Databases
Prospective Studies
Survival
sorafenib
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • Advanced disease
  • Kidney cancer
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology (medical)
  • Pharmacology

Cite this

Sorafenib tosylate in advanced kidney cancer : Past, present and future. / Porta, Camillo; Paglino, Chiara; Imarisio, Ilaria; Ferraris, Elisa.

In: Anti-Cancer Drugs, Vol. 20, No. 6, 07.2009, p. 409-415.

Research output: Contribution to journalArticle

@article{01303729fceb4bc49e73a26db480196a,
title = "Sorafenib tosylate in advanced kidney cancer: Past, present and future",
abstract = "The objective of this paper was to review the development of sorafenib tosylate in kidney cancer. The MedLine database, the Proceedings of the Annual American Society of Clinical Oncology meeting, as well as those of other key international meetings were extensively searched to identify relevant publications. Furthermore, the authors' direct experience with the drug was taken into account when commenting on the results retrieved. Sorafenib is a multikinase inhibitor that targets VEGF and PDGF receptors, other kinases, as well as the serine-threonine kinase Raf. Following early signs of activity from phase I and II studies, it has been shown to improve survival of pretreated advanced kidney cancer patients within a placebo-controlled, randomized, phase III trial, leading to its approval both in the United States and in Europe. Its activity has been subsequently confirmed in a real-world population by two expanded access programs performed globally, but not in a first-line setting; it also proved to be non-cross-resistant with two other molecularly targeted agents. Finally, its toxicity profile, which is acceptable and highly predictable, makes sorafenib appealing for combination treatments, especially with other molecularly targeted agents. Despite having been already demonstrated to be active in kidney cancer, the exact role of sorafenib in the first-line setting, in patients who have failed other molecularly targeted agents, and especially in combination with other agents, deserves further, prospective, studies.",
keywords = "Advanced disease, Kidney cancer, Sorafenib",
author = "Camillo Porta and Chiara Paglino and Ilaria Imarisio and Elisa Ferraris",
year = "2009",
month = "7",
doi = "10.1097/CAD.0b013e32831fb500",
language = "English",
volume = "20",
pages = "409--415",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Sorafenib tosylate in advanced kidney cancer

T2 - Past, present and future

AU - Porta, Camillo

AU - Paglino, Chiara

AU - Imarisio, Ilaria

AU - Ferraris, Elisa

PY - 2009/7

Y1 - 2009/7

N2 - The objective of this paper was to review the development of sorafenib tosylate in kidney cancer. The MedLine database, the Proceedings of the Annual American Society of Clinical Oncology meeting, as well as those of other key international meetings were extensively searched to identify relevant publications. Furthermore, the authors' direct experience with the drug was taken into account when commenting on the results retrieved. Sorafenib is a multikinase inhibitor that targets VEGF and PDGF receptors, other kinases, as well as the serine-threonine kinase Raf. Following early signs of activity from phase I and II studies, it has been shown to improve survival of pretreated advanced kidney cancer patients within a placebo-controlled, randomized, phase III trial, leading to its approval both in the United States and in Europe. Its activity has been subsequently confirmed in a real-world population by two expanded access programs performed globally, but not in a first-line setting; it also proved to be non-cross-resistant with two other molecularly targeted agents. Finally, its toxicity profile, which is acceptable and highly predictable, makes sorafenib appealing for combination treatments, especially with other molecularly targeted agents. Despite having been already demonstrated to be active in kidney cancer, the exact role of sorafenib in the first-line setting, in patients who have failed other molecularly targeted agents, and especially in combination with other agents, deserves further, prospective, studies.

AB - The objective of this paper was to review the development of sorafenib tosylate in kidney cancer. The MedLine database, the Proceedings of the Annual American Society of Clinical Oncology meeting, as well as those of other key international meetings were extensively searched to identify relevant publications. Furthermore, the authors' direct experience with the drug was taken into account when commenting on the results retrieved. Sorafenib is a multikinase inhibitor that targets VEGF and PDGF receptors, other kinases, as well as the serine-threonine kinase Raf. Following early signs of activity from phase I and II studies, it has been shown to improve survival of pretreated advanced kidney cancer patients within a placebo-controlled, randomized, phase III trial, leading to its approval both in the United States and in Europe. Its activity has been subsequently confirmed in a real-world population by two expanded access programs performed globally, but not in a first-line setting; it also proved to be non-cross-resistant with two other molecularly targeted agents. Finally, its toxicity profile, which is acceptable and highly predictable, makes sorafenib appealing for combination treatments, especially with other molecularly targeted agents. Despite having been already demonstrated to be active in kidney cancer, the exact role of sorafenib in the first-line setting, in patients who have failed other molecularly targeted agents, and especially in combination with other agents, deserves further, prospective, studies.

KW - Advanced disease

KW - Kidney cancer

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=67249141051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67249141051&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32831fb500

DO - 10.1097/CAD.0b013e32831fb500

M3 - Article

C2 - 19436197

AN - SCOPUS:67249141051

VL - 20

SP - 409

EP - 415

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 6

ER -